Riboflavin-responsive glutaryl CoA dehydrogenase deficiency.
We report here riboflavin responsiveness in a patient with glutaryl CoA dehydrogenase (GCDH) deficiency, compound heterozygous for the S139L and P248L mutations and with 20% residual GCDH enzyme activity in vitro. Our results suggest the mitochondrial GCDH homotetramer remains intact with one of these mutations associated with the binding site of the single FAD cofactor and that pharmacological doses of the cofactor precursor may be sufficient to induce an increase in activity in the mutant GCDH enzyme, although not sufficient to normalise urinary organic acid excretion. Serine139 is one of nine conserved amino acid residues that line the binding site of the protein and is in close proximity to both substrate and FAD cofactor. It is possible that steric alterations caused by substitution of serine with leucine at this position may be overcome with high cofactor concentrations. P248L is also associated with some residual GCDH activity in other patients and the unique combination of S139L with P248L may also explain the results in our patient. Responsiveness to riboflavin in our patient has been compared with two other patients with glutaric aciduria type 1 and minimal residual GCDH activity, one with homozygosity for the R257Q mutation and one with heterozygosity for the G354S mutation and a novel G156V mutation. A low lysine diet reduced glutaric acid excretion in our riboflavin-responsive GCDH-deficient patient almost to control values. She is now 21 years of age and clinically and neurologically normal.
Chalmers
Ronald A
RA
CIMOA, London NW1 0NH, UK. rachalmers@cimoa.org.uk
Bain
Murray D
MD
Zschocke
Johannes
J
D000328:Adult; D000592:Amino Acid Metabolism, Inborn Errors / Q000188:drug therapy* / Q000652:urine; D019943:Amino Acid Substitution; D002648:Child; D002675:Child, Preschool; D017809:Fatal Outcome; D005260:Female; D005977:Glutarates / Q000652:urine*; D050770:Glutaryl-CoA Dehydrogenase / Q000172:deficiency* / Q000235:genetics*; D006801:Humans; D007223:Infant; D008297:Male; D020836:Protein Structure, Quaternary; D012256:Riboflavin / Q000627:therapeutic use*
D005977:Glutarates; D050770:Glutaryl-CoA Dehydrogenase; C035736:glutaric acid; D012256:Riboflavin